glp 1 agonist new GLP-1 receptor agonists show promise in treating substance use disorders Curious about the latest in
Description
Due to the similar molecular mechanism between T2DM and AD, several drugs for the treatment of T2DM are increasingly being proposed for the treatment of AD (82)
Challenges and future directions Currently, GLP-1RAs have shown potential for mitigating neurodegeneration
Semaglutide, a type of GLP-1R agonists with 94% sequence homology to GLP-1 and with an extended half-life of approximately 1 week, has been clinically approved to treat T2DM and is available in subcutaneous and oral dosage form (136, 137)
In addition, exendin-4 at 0.1100 nM concentrations for 2496 h increased GLP-1R activation, p53, p21, p38, cAMP, Bax/Bcl-2 ratio, and p38/MAPK activation
